t
On 5 March 2026, Beximco Pharmaceuticals PLC announced an update on the timeline for two outstanding Writ Petitions. The hearing of Writ Petition No. 525 of 2025, challenging the Bangladesh Securities and Exchange Commission's proposed appointment of nine additional independent non-executive directors, and Writ Petition No. 1243 of 2026, challenging the BSEC's order to hold a Board Meeting for these directors, will now commence after the High Court's vacation. This vacation is scheduled from 15 March 2026 to 18 April 2026.
| Date | 5 Mar 2026 |
| Time | 09:13:43 |
| Category | Miscellaneous |
| ID | 4933V |
5 March 2026
BEXIMCO PHARMACEUTICALS PLC.
Update on Writ Petitions
Beximco Pharmaceuticals PLC. ("the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, provides an update regarding the timeline for its outstanding Writ Petitions to be heard by the High Court Division of the Supreme Court of Bangladesh.
Further to previous announcements, the hearing of Writ Petition No. 525 of 2025 (challenging the proposed appointment by the Bangladesh Securities and Exchange Commission of nine additional independent non-executive directors to the Company's Board) and Writ Petition No. 1243 of 2026 (challenging the BSEC's order to hold a Board Meeting onboarding the nine additional independent directors) will now commence after the scheduled vacation (from 15 March 2026 to 18 April 2026) of the High Court Division of the Supreme Court of Bangladesh.
For further information please visit www.beximcopharma.com or enquire to:
|
Beximco Pharma |
|
Mohammad Ali Nawaz, Chief Financial Officer Tel: +880 2 58611001, Ext. 20030
Mohammad Asad Ullah, FCS Executive Director & Company Secretary Tel: +880 2 41060531, Ext. 10140
|
|
SPARK Advisory Partners Limited (Nominated Adviser) Mark Brady / Andrew Emmott Tel: +44 (0)20 3368 3551 / 3555
|
|
SP Angel Corporate Finance LLP (Broker) Matthew Johnson Tel: +44 (0) 20 3470 0470
|
|
FTI Consulting Simon Conway / Sam Purewal Tel: +44 (0)20 3727 1000
|
Notes to Editors
About Beximco Pharmaceuticals PLC
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.